文献速递消化道肿瘤放疗

局部进展期胃癌患者术前放化疗诱导的血液学毒性及相关椎体剂量学评估:一项III期临床试验数据

Preoperative chemoradiation-induced hematological toxicity and related vertebral dosimetry evaluations in patients with locally advanced gastric cancer: data from a phase III clinical trial.
PubMed 文献 · Radiat Oncol · 2023-06-09

该研究基于III期随机临床试验(NCT01815853)中302例局部进展期胃癌患者,比较新辅助放化疗(nCRT)与新辅助化疗(nCT)的血液学毒性,并分析椎体剂量学参数对毒性的预测价值。结果显示nCRT组3级及以上血液学毒性发生率高于nCT组,椎体V5<88.75%与3级及以上白细胞减少、血小板减少及总血液学毒性风险降低相关。

要点

  • nCRT组3级及以上血液学毒性发生率高于nCT组,训练队列27.4% vs 16.2%(P=0.042),验证队列35.0% vs 13.2%(P=0.025)。
  • 椎体V5与3级及以上白细胞减少、血小板减少及总血液学毒性独立相关。
  • V5<88.75%可提示3级及以上血液学毒性风险降低,在训练及外部验证队列中均得到验证。

核心结论

  • 与nCT相比,nCRT可能增加局部进展期胃癌患者3级及以上血液学毒性风险。
  • 受照椎体V5<88.75%的剂量约束可降低3级及以上血液学毒性发生率。

研究设计与样本

  • 研究纳入正在进行的多中心随机临床试验(NCT01815853)中302例胃癌患者,来自两个主要中心,分为训练队列和外部验证队列。
  • nCT组接受三个周期XELOX化疗,nCRT组接受相同剂量减量的化疗加45 Gy放疗。
  • 回顾性勾画椎体并提取nCRT组剂量体积参数,比较nCT与nCRT组基线、新辅助治疗期间及术前全血细胞计数。
  • 血液学毒性按CTCAE v5.0分级,采用ROC曲线确定剂量学变量的最佳截断点并在训练和外部验证队列中验证预测效能。

主要发现

  • 训练队列中nCRT组3级及以上血液学毒性发生率为27.4%,nCT组为16.2%(P=0.042)。
  • 验证队列中nCRT组3级及以上血液学毒性发生率为35.0%,nCT组为13.2%(P=0.025)。
  • 训练队列多因素分析显示V5与3级及以上白细胞减少(P=0.000)、3级及以上血小板减少(P=0.001)及3级及以上总血液学毒性(P=0.042)相关。
  • Spearman相关分析显示V5与白细胞最低值(P=0.0001)及血小板最低值(P=0.0002)显著相关。
  • ROC曲线确定V5最佳截断点,V5<88.75%可提示训练队列及外部验证队列中3级及以上白细胞减少、血小板减少及总血液学毒性风险降低。

关键数值与推荐

  • 血液学毒性分级依据CTCAE v5.0。
  • nCRT组放疗剂量为45 Gy,化疗为剂量减量的XELOX方案。
  • V5<88.75%作为预测3级及以上血液学毒性风险降低的剂量学截断值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To explore the hematological toxicity (HT) induced by neoadjuvant chemoradiotherapy (nCRT) compared with neoadjuvant chemotherapy (nCT) and to identify the appropriate vertebral body (VB) dosimetric parameters for predicting HT in patients with locally advanced gastric cancer (GC). METHODS: In the phase III study, 302 patients with GC from an ongoing multi-center randomized clinical trial (NCT01815853) were included. Patients from two major centers were grouped into training and external validation cohorts. The nCT group received three cycles of XELOX chemotherapy, while the nCRT received the same dose-reduced chemotherapy plus 45 Gy radiotherapy. The complete blood counts at baseline, during neoadjuvant treatment, and in the preoperative period were compared between the nCT and nCRT groups. The VB was retrospectively contoured and the dose-volume parameters were extracted in the nCRT group. Patients' clinical characteristics, VB dosimetric parameters, and HTs were statistically analyzed. Instances of HT were graded according to the Common Terminology Criteria for Adverse Events v5.0 (CTCAE v5.0). The receiver operating characteristic (ROC) curves were generated to identify the optimal cut-off points for dosimetric variables and verify the prediction efficiency of the dosimetric index in both training and external validation cohorts. RESULTS: In the training cohort, 27.4% Grade 3 + HTs were noted in the nCRT group and 16.2% in the nCT group (P = 0.042). A similar result was exhibited in the validation cohort, with 35.0% Grade 3 + HTs in the nCRT group and 13.2% in the nCT group (P = 0.025). The multivariate analysis of the training cohort revealed that V5 was associated with Grade 3 + leukopenia (P = 0.000), Grade 3 + thrombocytopenia (P = 0.001), and Grade 3 + total HTs (P = 0.042). The Spearman correlation analysis identified a significant correlation of V5 with the white blood cell nadir (P = 0.0001) and platelet nadir (P = 0.0002). The ROC curve identified the optimal cut-off points for V5 and showed that V5 < 88.75% could indicate a decreased risk of Grade 3 + leukopenia, thrombocytopenia, and total HTs in the training as well as the external validation cohorts. CONCLUSIONS: Compared with nCT, nCRT could increase the risk of Grade 3 + HT in patients with locally advanced GC. Dose constraints of V5 < 88.75% in irradiated VB could reduce the incidence of Grade 3 + HT.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wang JJ, Shao H, Zhang L, et al. Preoperative chemoradiation-induced hematological toxicity and related vertebral dosimetry evaluations in patients with locally advanced gastric cancer: data from a phase III clinical trial. Radiat Oncol. 2023. PMID: 37365597. doi:10.1186/s13014-023-02269-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。